Literature DB >> 32773818

[Severe acute respiratory syndrome coronavirus 2 infection in renal transplant recipients: A case report].

Q Y Li1, Q Cheng1, Z L Zhao2, N N Dai1, L Zeng3, L Zhu4, W Guo5, C Li2, J H Wang6, S Li6, Q G Ge2, N Shen1.   

Abstract

The novel coronavirus is a newly discovered pathogen in late December 2019, and its source is currently unknown, which can lead to asymptomatic infection, new coronavirus pneumonia or serious complications, such as acute respiratory failure. Corona virus disease 2019 (COVID-19) is a new type of respiratory disease that is currently spreading all over the world and caused by this coronavirus. Its common symptoms are highly similar to those of other viruses, such as fever, cough and dyspnea. There is currently no vaccine or treatment for COVID-19. Everyone is susceptible to infection with this disease, and owing to the long-term use of immunosuppressants, the immunity of kidney transplant recipients is suppressed, and it is more likely to be infected with the disease. At present, its impact on kidney transplant recipients is unclear. This article reports the clinical features and therapeutic course of novel coronavirus infection in a patient after renal transplantation. A 37-year-old female patient who received a kidney transplant 6 months before was diagnosed with novel coronavirus pneumonia. The patient's symptoms (such as fever, chills, dry cough, muscle aches), laboratory tests (such as decreased white blood cell count, elevated liver enzymes and D-dimer, positive viral nucleic acid test), and chest CT (multiple left lower lung plaque ground glass shadow) were similar to those of non-transplanted novel coronavirus pneumonia patients. In terms of treatment, because the immunity of kidney transplant recipients has been suppressed for a long time, it is a very common strategy to suspend the use of immunosuppressive agents. Therefore, the patient immediately discontinued the immunosuppressive agent after admission, so that she could restore immunity against infection in a short time. At the same time, the use of glucocorticoids was also very important. Its immunosuppressive and anti-inflammatory effects played a large role in the treatment process.In addition, prophylactic antibiotics was needed, and nephrotoxic drugs should be used with caution. Finally, following discounting the use of immunosuppressant and a low-dose glucocorticoid-based treatment regimen, COVID-19 in this renal transplant recipient was successfully cured. The cure of this case was of great significance, and this adjuvant nonspecific antiviral therapy could provide a template for the treatment of other such patients.

Entities:  

Keywords:  Corona virus disease 2019; Immunosuppressive agents; Kidney transplantation

Mesh:

Year:  2020        PMID: 32773818      PMCID: PMC7433616     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  6 in total

1.  Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study.

Authors:  Deepali Kumar; Marian G Michaels; Michele I Morris; Michael Green; Robin K Avery; Catherine Liu; Lara Danziger-Isakov; Valentina Stosor; Michele Estabrook; Soren Gantt; Kieren A Marr; Stanley Martin; Fernanda P Silveira; Raymund R Razonable; Upton D Allen; Marilyn E Levi; G Marshall Lyon; Lorraine E Bell; Shirish Huprikar; Gopi Patel; Kevin S Gregg; Kenneth Pursell; Doug Helmersen; Kathleen G Julian; Kevin Shiley; Bartholomew Bono; Vikas R Dharnidharka; Gelareh Alavi; Jayant S Kalpoe; Shmuel Shoham; Gail E Reid; Atul Humar
Journal:  Lancet Infect Dis       Date:  2010-07-09       Impact factor: 25.071

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Corticosteroids as adjunctive therapy in the treatment of influenza.

Authors:  Louise Lansbury; Chamira Rodrigo; Jo Leonardi-Bee; Jonathan Nguyen-Van-Tam; Wei Shen Lim
Journal:  Cochrane Database Syst Rev       Date:  2019-02-24

4.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

5.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

Authors:  Clark D Russell; Jonathan E Millar; J Kenneth Baillie
Journal:  Lancet       Date:  2020-02-07       Impact factor: 79.321

6.  Identification of Kidney Transplant Recipients with Coronavirus Disease 2019.

Authors:  Hui Zhang; Yan Chen; Quan Yuan; Qiu-Xiang Xia; Xian-Peng Zeng; Jing-Tao Peng; Jing Liu; Xing-Yuan Xiao; Guo-Song Jiang; Han-Yu Xiao; Liang-Bo Xie; Jing Chen; Jia-Li Liu; Xiong Xiao; Hua Su; Chun Zhang; Xiao-Ping Zhang; Hua Yang; Heng Li; Zhen-Di Wang
Journal:  Eur Urol       Date:  2020-04-02       Impact factor: 20.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.